U.S. Naloxone Market, By Drug Type, By Route of Administration, By Distribution Channel

PUBLISHED: February 19, 2025

PAGES: 198 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global U.S. Naloxone Market is estimated to be valued at USD 607.7 Mn in 2025 and is expected to reach USD 1,215.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 607.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.40%	2032 Value Projection:	USD 1,215.5 Mn

Figure. U.S. Naloxone Market Share (%), By Drug Type 2025

U.S. naloxone market growth is driven by ongoing opioid crisis. Naloxone is an opioid antagonist that is used for the complete or partial reversal of opioid overdose, including reversal of respiratory depression, sedation, and hypotension. It works by blocking or reversing the effects of opioids by binding to the opioid receptors. With the exponential rise in opioid overdoses and deaths involving prescription pain medications and heroin in the U.S., naloxone play an important role in reducing mortality caused by opioid overdose events. Its wide availability in both pharmacy and non-prescription settings has improved accessibility. The CDC recommends co-prescribing of Naloxone with prescription opioids in high-risk cases to prevent overdose deaths.

Market Dynamics:

U.S. naloxone market growth is driven by growing opioid epidemic w that results in a large number of opioid overdose deaths over the past few decades. Increasing prevalence of prescription pain reliever and heroin abuse also drives the market growth. However, pricing pressures and lower brand name drug revenues amid generic competition can hamper the market growth. Higher accessibility of Naloxone formulations like intranasal spray and auto-injectors as well as collaborations to expand access can offer significant growth opportunities. Initiatives by state and federal agencies to promote naloxone co-prescription and wider distribution through community programs can also drive the market growth.

Key Features of the Study:

This report provides in-depth analysis of the U.S. naloxone market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the U.S. naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Adapt Pharma Inc., Mylan N.V., Hospira Inc. (Pfizer Inc.), Kaleo Inc., Amphastar Pharmaceuticals Inc., Emergent BioSolutions Inc., Indivior PLC, Akorn, Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz (a Novartis division), Teva Pharmaceuticals, Amneal Pharmaceuticals, Somerset Pharma, LLC, Orexo AB, UCB Pharma, West Ward Pharmaceuticals, Purdue Pharma.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

U.S. naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. naloxone market

Detailed Segmentation-

By Drug Type
- Branded
- Generic
By Route of Administration
- Intranasal Administration
- Intramuscular Administration
- Intravenous Administration
- others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles:
- Adapt Pharma Inc.
- Mylan N.V.
- Hospira Inc. (Pfizer Inc.)
- Kaleo Inc.
- Amphastar Pharmaceuticals Inc.
- Emergent BioSolutions Inc.
- Indivior PLC
- Akorn, Inc.
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Sandoz (a Novartis division)
- Teva Pharmaceuticals
- Amneal Pharmaceuticals
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma
- West Ward Pharmaceuticals
- Purdue Pharma

Product Code: CMI4953

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. U.S. Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. U.S. Naloxone Market, By Drug Type, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Branded
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Generic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. U.S. Naloxone Market, By Route of Administration, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intranasal Administration
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Intramuscular Administration
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Intravenous Administration
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. U.S. Naloxone Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Competitive Landscape

Company Profiles
- Adapt Pharma Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Hospira Inc. (Pfizer Inc.)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kaleo Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amphastar Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Emergent BioSolutions Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Indivior PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Akorn, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Hikma Pharmaceuticals PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sandoz (a Novartis division)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amneal Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Somerset Pharma, LLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Orexo AB
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- UCB Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- West Ward Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Purdue Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies